Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for ...

MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients ...

Many patients with ER-positive/HER2-negative advanced breast cancer eventually develop resistance to standard first-line ...

About Myriad Oncology Myriad Oncology provides a portfolio of advanced genetic and tumor genomic testing solutions, including risk assessment, screening, tools to aid treatment guidance ...

Myriad Genetics, (NASDAQ:MYGN) listed on the NASDAQ under the ticker MYGN, operates in the therapeutics sector and aligns ...

Myriad Genetics, Inc. (NASDAQ:MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies that underscore major advances in molecular diagnostics and precision ...

Detailed price information for Sophia Genetics Sa (SOPH-Q) from The Globe and Mail including charting and trades.

Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

Inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis, has long been considered a modern ...

Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful ...